对Oligo-1,6-Glucosidase进行结构分析和分子工程,以缓解产品抑制
Jinshu Zhang1,2, Haocun Kong2, Yixiong Tian3,1
1School of Food Science and Technology, Jiangnan University, Wuxi 214122, China.
Journal of agricultural and food chemistry
|August 26, 2025
概括
研究人员设计了oligo-1,6-glucosidase以克服产品的抑制,提高其在葡萄糖生产中的效率. 在高血糖度下,三重突变剂显著改善了酶活性和稳定性.
科学领域:
- 生物化学
- 酵素学
- 结构生物学
背景情况:
- 奥利戈-1,6-葡萄糖酶对于异多糖糖中的α-1,6-糖键的水解至关重要.
- 产品抑制限制了橄-1,6-葡萄糖酶的工业应用,特别是在葡萄糖生产中.
研究的目的:
- 阐明Paenibacillus sp中的产品抑制的结构基础. STB16 橄-1,6-葡萄糖酶 (pspOGA) 的使用.
- 设计pspOGA以减少产品抑制和提高高葡萄糖环境中的性能.
主要方法:
- 用X射线结晶学来确定pspOGA的结构.
- 定位突变 (V219A,V219A/K311M/E405A) 用于对酶进行工程.
- 在高葡萄糖度和葡萄糖母液中测试酶活性.
- 循环二元化和分子动力学模拟以阐明机制.
主要成果:
- 晶体结构显示了基质通道特征和Val219在基质特异性的作用.
- 三重突变的V219A/K311M/E405A显著减轻了产品的抑制作用.
- 在V219A的6. 25%相比,三重突变在500mg/ ml葡萄糖下保持了49. 36%的活性.
- 产品抑制常数 (Ki) 增加了1. 3倍,表明产品的结合力减弱.
结论:
- 针对特定残留物的合理设计可以有效地降低产品在oligo-1,6-glucosidase中的抑制.
- 工艺化pspOGA在葡萄糖生产和副产品价值化方面表现出更强的工业应用性.
- 结构洞察力为进一步的酶优化提供了基础.
相关概念视频
Oligosaccharide Assembly
3.0K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
3.0K
Enzyme Inhibition
79.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
256


